Anticancer metal drugs and immunogenic cell death

Area of Science:

• Oncology
• Immunology
• Materials Science

Background:

• Chemotherapeutics and precision anticancer agents are typically viewed as targeting cancer cells directly.
• Emerging evidence shows these compounds possess immunomodulatory activities, offering synergistic anticancer potential.
• Immunogenic cell death (ICD) represents a key interaction between chemotherapy and the immune response, observed as a vaccination effect in mouse models.

Purpose of the Study:

• To review the existing literature on anticancer metal drugs and their ability to induce ICD.
• To explore the potential of novel metal complexes as ICD inducers in cancer therapy.
• To recommend further investigation into the immunogenic properties of experimental anticancer metal drugs.

Main Methods:

• Literature review of existing studies on anticancer metal drugs and ICD.
• Analysis of the relationship between reactive oxygen species (ROS), endoplasmic reticulum (ER) stress, and ICD.
• Examination of known ICD inducers, such as oxaliplatin, in the context of metal-based drugs.

Main Results:

• While not structurally or mechanistically predictable, ICD induction is linked to ROS generation and ER stress.
• Oxaliplatin is identified as an ICD inducer, whereas cisplatin is not.
• Experimental metal compounds are known to mediate ROS and ER stress, suggesting potential for ICD induction.

Conclusions:

• The immunogenic potential of experimental anticancer metal drugs warrants deeper investigation.
• Metal-based compounds could offer novel strategies for inducing ICD and enhancing cancer immunotherapy.
• A comprehensive understanding of ICD mechanisms could lead to more effective combination cancer therapies.